In April 2013, Former SBIR firm MedImmune (itself now a unit of AstraZeneca) acquired AlphaCore Pharma Inc. Now operating as a subsiduary of AstraZeneca, AlphaCore Pharma is developing ACP-501 (recombinant human lecithin:cholesterol acyltransferase or rhLCAT) as a cardiovascular therapy for acute coronary syndromes, or other high-risk atherosclerosis populations. Additionally, ACP-501 will be developed to treat familial LCAT deficiency (an orphan designated enzyme replacement therapy) and other diseases where LCAT activity is low. Founded by three former Pfizer employees, AlphaCore Pharma Inc early specialized in clinical research for a protein that could help treat cardiovascular disease.
